GENE ONLINE|News &
Opinion
Blog

2022-04-26| Startups

Birmingham University Spinout Looking to Tackle Ocular Surface Disorders

by Fujie Tham
Share To

The University of Birmingham formed a new spinout, Healome Therapeutics Ltd to commercialize a healing platform for preventable blindness. With backing of the UK Medical Research Council, Healome is ready to progress from lab bench to completing Phase I human trials and establishing its base in Birmingham Research Park.

Healome’s prime application will be tackling ocular surface disorders, which are challenging to treat and have progressively larger impacts on patients’ quality of life. The company has raised £2.8m grant funding from the Medical Research Council (MRC) and £1.3m from the National Institute of Health and Care Research (NIHR) Invention for Innovation program. Its founding directors already have experience in commercializing and advancing therapies toward Phase I-III clinical trials.

Related Article: Novartis Books Gyroscope for $1.5 Billion in Pursuit of Gene Therapy for Blindness

 

Gel-Like Ocular Bandages Can Be Applied Like Daily Eye Drops

 

The core technology is a gel-like material that flows like a liquid, and self-structures into a clear protective layer over the eye surface which is gradually dispersed and cleared away by blinking over preset hours. The gel can be used alone or as a carrier to deliver other therapeutics. Studies demonstrated that one of Healome’s formulations has anti-scarring activity, and healing properties are augmented by combining it with other therapeutics. Treatments using this gel platform will likely come in a clear degradable “ocular bandages” form that can be applied just like our daily eye drops.

“Ocular surface diseases leading to Dry Eye have a disproportionately large impact on health, well-being, and the ability to enjoy life. These conditions can also be very expensive for patients to manage. There are many unmet patients, clinical and industrial needs in this area, which Healome Therapeutics is well-placed to address,” said Dr. Richard Williams, Healome CEO.

Inaugurated by the University of Birmingham and Birmingham City Council in 1986, the Birmingham Science Park accommodates companies and projects seeking to work with the University in research, development, and training. This March, the park announced that specialist infectious disease diagnostics company, Genetic Signatures joined BioHub Birmingham as the launchpad for a planned further expansion into Europe, the Middle East, and Africa.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
European Pharmaceutical Review Highlights RNA Therapeutics and Process Analytical Technology in 2025 Issue 1
2025-03-21
Researchers Achieve High Throughput in Nanomaterial Development for Drug Delivery
2025-03-15
Roche Offers Up to $1 Billion for Avista to Develop Eye Disease Vectors
2022-07-20
LATEST
Study Finds ADHD Prevalence Unchanged Amid Ongoing Medication Shortages
2025-06-18
FDA Panel Discusses Streamlining Drug Approvals for Rare Disease Therapies
2025-06-18
SCHOTT Pharma Allocates €100 Million to Boost RTU Sterile Cartridge Production Capacity
2025-06-18
European Commission Approves Fixed-Duration Regimen of Calquence and Venetoclax for Chronic Lymphocytic Leukemia
2025-06-18
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Cancer Drug Pembrolizumab
2025-06-18
Atopic Dermatitis Market in Seven Major Global Regions Projected to Reach $22.4 Billion by 2033
2025-06-18
Servier India Launches Ivosidenib for AML and Cholangiocarcinoma Patients with IDH1 Mutation Following CDSCO Approval
2025-06-18
EVENT
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top